Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Novartis AG (NYSE:NVS)

79.55
Delayed Data
As of Aug 25
 -0.75 / -0.93%
Today’s Change
69.90
Today|||52-Week Range
98.97
-7.54%
Year-to-Date
Why Momenta Pharmaceuticals Shares Made a Late-Day Jump Higher
Aug 24 / MotleyFool.com - Paid Partner Content
Novartis: First-Class Pharmaceuticals
Aug 19 / GuruFocus News - Paid Partner Content
Merck Offers Value and Steady Dividend Growth
Aug 24 / GuruFocus News - Paid Partner Content
Better Buy: Amgen Inc. vs. Biogen
Aug 17 / MotleyFool.com - Paid Partner Content
Novartis Licenses Anti-PCSK9 Antibody to Cyon Therapeutics
Aug 24 / Zacks.com - Paid Partner Content
Allergan to Buy ForSight VISION5, Boost Glaucoma Pipeline
Aug 15 / Zacks.com - Paid Partner Content
3 Reasons Medivation Is the Juiciest Target in Biotech
Aug 21 / MotleyFool.com - Paid Partner Content
 

Today’s Trading

Previous close80.30
Today’s open79.67
Day’s range77.66 - 80.13
Volume1,593,686
Average volume (3 months)1,725,907
Market cap$186.6B
Dividend yield3.42%
Data as of 08/25/2016

Growth & Valuation

Earnings growth (last year)+77.51%
Earnings growth (this year)--
Earnings growth (next 5 years)+5.15%
Revenue growth (last year)-4.75%
P/E ratio28.7
Price/Sales4.25
Price/Book2.47

Competitors

 Today’s
change
Today’s
% change
AGNPRAAllergan plc-11.00-1.28%
MRKMerck-0.41-0.65%
PFEPfizer-0.05-0.14%
GSKGlaxoSmithKline-0.16-0.36%
Data as of 08/25/2016

Financials

Next reporting dateOctober 25, 2016
EPS forecast (this quarter)$1.20
Annual revenue (last year)$49.4B
Annual profit (last year)$17.8B
Net profit margin14.19%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Major
Chief Executive Officer
Joseph Jimenez
Chief Financial Officer
Harry Kirsch
Corporate headquarters
Basel, Basel-stadt (basle Town)

Forecasts

Partner Offers

Search for Jobs